ALKEM2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member ALKEM2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2019-04-01 2020-03-31 2020-05-26 INR Millions Yearly Single segment The Company is exclusively engaged in pharmaceutical business 2020-01-01 2020-03-31 Audited Standalone 16875200000.00 259200000.00 17134400000.00 4263700000.00 1786000000.00 775800000.00 2255500000.00 95100000.00 637600000.00 4256400000.00 14070100000.00 3064300000.00 0.00 3064300000.00 981202000.00 -629000000.00 352202000.00 0.00 2712098000.00 0.00 0.00 0.00 0.00 2712098000.00 -161400000.00 2550698000.00 0.00 0.00 239100000.00 2 22.68 22.68 0.00 0.00 22.68 22.68 1. The above audited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 04.06.2020 and subsequently approved by the BOD at its meeting held on 05.06.2020. The auditors have expressed an unmodified opinion on the financial results for the year ended 31.03.2020. The figures for the quarter ended 31.03.2020 and 31.12.2019 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31.12.2019 and 31.12. 2018 respectively, which were subjected to limited review. n n2. In March 2020, the WHO declared COVID-19 to be a pandemic and several restrictions have been imposed by the Governments across the globe on travel, goods movement and transportation considering public health and safety measures. Considering the Company’s products are classified as an ‘essential commodity’, management believes that the impact of the pandemic may not be significant. As of today, production facilities remain operational, following enhanced internal safety guidelines. The Company follows a multi-sourcing strategy for its raw materials allowing the Company to hedge supply risks and ensure reliable supply. The Company also maintains strategic safety stocks to ensure availability of raw materials and formulated products. The Company has considered internal and external information while assessing recoverability of its assets disclosed in the financial statement upto the date of approval of these financial results by the BOD. Based on such assessment and considering the current economic indicators, the Company expects to recover the carrying amount of these assets. BOD has also considered the impact of COVID-19 on the business for the foreseeable future and have concluded that the Company has sufficient resources to continue as a going concern. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions. n n3. Pursuant to the Taxation Law (Amendment) Ordinance, 2019 issued by Ministry of Law and Justice (Legislative Department) on 20.09.2019 which is effective 1.04.2019, domestic companies have the option to pay corporate income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Company has made an assessment of the impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated MAT credit. n n4. Effective 1.04.2019, the Company has adopted Ind AS 116 Leases applicable to all contracts having lease components existing on 1.04.2019 using modified retrospective approach. This has resulted in recognising right of use asset and a corresponding lease liability of Rs.646.2 million as at 1.04.2019. In the statement of profit and loss for the current period, operating lease expenses has changed from lease rent to depreciation cost for the right of use asset and finance cost for interest accrued on lease liability. Due to this change, profit before tax for the quarter and year ended 31.03. 2020 is lower by Rs.9.0 million and Rs.25.6 million respectively. Consequent to adoption of Ind AS 116, there is no impact on retained earnings as on 1.04.2019 resulting in no restatement in results of comparative period. n n5.The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. n n6. During the QE 31.03.2020, the Company has paid an interim dividend of Rs. 22/- per equity share (1100% on the face value of Rs. 2 each) for the financial year 2019-20. The Board of Directors at its meeting held on 05.06.2020 has recommended a final dividend of Rs. 3 per equity share (150% on the face value of Rs. 2 each) for the financial year 2019-20. Single segment 2019-04-01 2020-03-31 Audited Standalone 66770800000.00 959800000.00 67730600000.00 17998700000.00 7843800000.00 -336900000.00 10667600000.00 387100000.00 1868400000.00 15921100000.00 54349800000.00 13380800000.00 0.00 13380800000.00 2469502000.00 -1732900000.00 736602000.00 0.00 12644198000.00 0.00 0.00 0.00 0.00 12644198000.00 -172800000.00 12471398000.00 0.00 0.00 239100000.00 2 0.00 105.75 105.75 0.00 0.00 105.75 105.75 Other Expenses 4256400000.00 Other Expenses 15921100000.00